Is Xilio Therapeutics, Inc. (XLO) a Buy, Sell, or Hold?
NASDAQ : XLO
Xilio Therapeutics, Inc. — Insider Trades
$9.05 USD
-$0.13 (-1.42%)
- Volume
- 9.31K
- Average Volume
- 43.68K
- Market Capitalization
- $59.51M
- P/E Ratio
- -6.07
- Dividend Yield
- 0.00%
- Price Target
- $98.00
- Year High
- $12.74
- Year Low
- $6.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.25
Insider Activity Summary (Last 12 Months)
Insiders Buying
64
Insiders Selling
31
Amount of Insider Selling
$16.8M
XLO Insider Buying/Selling by Quarter
XLO Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Bello Akintunde Olatokumbo | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Shannon James Samuel | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Curran Daniel J. | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Xu Yuan | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| ROSS ROBERT W. | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Bonstein Sara | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Brennan Aoife | director | 2026-06-11 | A-Award | 7.99 | 2026-06-12 |
| Blanchard Cheryl R | director | 2026-04-15 | A-Award | 8.4 | 2026-04-16 |
| Blanchard Cheryl R | 2026-04-15 | 0 | 2026-04-16 | ||
| Shannon James Samuel | director | 2026-03-26 | P-Purchase | 8.79 | 2026-03-30 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2026-02-13 | P-Purchase | 0.0001 | 2026-02-17 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-12-31 | A-Award | 0.841 | 2026-01-05 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-12-31 | A-Award | 0.841 | 2026-01-05 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2026-01-02 | S-Sale | 0.6432 | 2026-01-05 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-12-31 | A-Award | 0.841 | 2026-01-05 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2026-01-02 | S-Sale | 0.6432 | 2026-01-05 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-12-31 | A-Award | 0.841 | 2026-01-05 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2026-01-01 | M-Exempt | 0 | 2026-01-05 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-11-26 | X-InTheMoney | 0.0001 | 2025-12-01 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-11-26 | X-InTheMoney | 0.7499 | 2025-12-01 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 0.841 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | A-Award | 0.841 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | A-Award | 1 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | A-Award | 1 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | A-Award | 1 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 2.785 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 2.69 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 16 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 2.13 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 6.65 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 2.75 | 2025-11-25 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-11-21 | D-Return | 12.66 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | D-Return | 3.17 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | D-Return | 1.08 | 2025-11-25 |
| Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 2025-11-21 | D-Return | 2.785 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 0.841 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | D-Return | 2.79 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | D-Return | 9.69 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | D-Return | 2.37 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | D-Return | 2.69 | 2025-11-25 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-11-21 | D-Return | 2.785 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 0.841 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | A-Award | 1.5 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 12.66 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 13.83 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 2.785 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 5.51 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 5.89 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 16 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 2.69 | 2025-11-25 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-11-21 | D-Return | 11.69 | 2025-11-25 |
| Shannon James Samuel | director | 2025-06-17 | P-Purchase | 0.6886 | 2025-06-18 |
| Shannon James Samuel | director | 2025-06-16 | P-Purchase | 0.686 | 2025-06-18 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-06-16 | P-Purchase | 0.6801 | 2025-06-18 |
| Russo Rene | 2025-01-01 | 0 | 2025-06-18 | ||
| ROSS ROBERT W. | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Brennan Aoife | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Bonstein Sara | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Curran Daniel J. | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Clancy Paul J | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Xu Yuan | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Shannon James Samuel | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Rossi Christina | director | 2025-06-11 | A-Award | 0.693 | 2025-06-12 |
| Bello Akintunde Olatokumbo | director | 2025-06-10 | A-Award | 0.7 | 2025-06-12 |
| Bello Akintunde Olatokumbo | 2025-06-10 | 0 | 2025-06-12 | ||
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-06-05 | P-Purchase | 0.0001 | 2025-06-06 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-06-05 | P-Purchase | 0.75 | 2025-06-06 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-06-05 | P-Purchase | 0.75 | 2025-06-06 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2025-06-05 | P-Purchase | 0.75 | 2025-06-06 |
| Russo Rene | director, officer: PRESIDENT AND CEO | 2025-04-15 | A-Award | 0.712 | 2025-04-16 |
| Frankenfield Christopher James | officer: Chief Financial Officer | 2025-04-15 | A-Award | 0.712 | 2025-04-16 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-01-01 | A-Award | 0.955 | 2025-01-03 |
| Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | 2025-01-01 | M-Exempt | 0 | 2025-01-03 |